Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORA PDE6B Gene Therapy in PDE6B Retinitis Pigmentosa
2024-511687-90-00Phase 2Completed
- Sponsor
- eyeDNA Therapeutics
- Start
- May 2024
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AAV2/5-hPDE6B in retinitis pigmentosa (RP), sponsored by eyeDNA Therapeutics. Primary endpoint: Safety endpoints. Started May 2024; status: completed.
02
Drugs
AAV2/5-hPDE6B
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on 2024-511687-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511687-90-00.